Skip to main
PRVA
PRVA logo

PRVA Stock Forecast & Price Target

PRVA Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 67%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Privia Health Group Inc has shown strong execution in value-based care partnerships, evidenced by a 20% year-over-year increase in MSSP beneficiaries following a $25 million acquisition in February 2023, alongside a notable improvement in savings rates by 150 basis points. The company has successfully integrated over 100 providers into its platform, highlighting its operational capabilities and commitment to enhancing physician practices. Additionally, while Privia is focused on expanding through large health systems, the potential for organic growth among individual physicians will be crucial in achieving its long-term growth targets.

Bears say

Privia Health Group Inc. faces a challenging outlook due to anticipated declines in Medicaid enrollment, as indicated by the guidance from its Medicaid operating partners. The company expects an 8%-10% decrease in Medicaid membership on a same-store basis by the end of the year, stemming from re-determination activities following the conclusion of the public health emergency. This expected decline could adversely affect Privia's revenue and overall financial performance, raising concerns about its future growth prospects.

PRVA has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 67% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Privia Health Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Privia Health Group (PRVA) Forecast

Analysts have given PRVA a Buy based on their latest research and market trends.

According to 12 analysts, PRVA has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Privia Health Group (PRVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.